Duane Mitchell

Immunomic Therapeutics Announces Open Enrollment for RENEW Clinical Study of CMV RNA-Pulsed Dendritic Cell Vaccine for the Treatment of Newly-Diagnosed Glioblastoma Patients

Retrieved on: 
Tuesday, November 30, 2021
Science, Other Science, Biotechnology, Research, Oncology, Health, Clinical Trials, Other Health, World Health Organization, ITI, Death, GBM, Company, Lysosome-associated membrane glycoprotein, Diagnosis, WHO, History, DNA, B cell, Biotechnology, Allergy, Infection, UNITE, Brain, Glioblastoma, World, Cancer, Acute myeloid leukemia, University, LAMP1, The Society of Neurological Surgeons, American Association of Neurological Surgeons, Duane Mitchell, Trial of the century, Degenerative disease, Partnership, American Brain Tumor Association, Human, Temozolomide, Vaccine, Survival, Adult, ATTAC, Therapy, American Association, Association, Patient, Duke University School of Medicine, LAMP, Duke University, Chemoradiotherapy, Antigen presentation, Astellas Pharma, Patent, Immunomics, RNA, Astrocyte, DC, CMV, Pharmaceutical industry, Glioblastoma (GBM), ITI-1000 and the Phase 2 (ATTAC-II) Study, UNITE, Immunomic Therapeutics, Inc., GLIOBLASTOMA (GBM), ITI-1000 AND THE PHASE 2 (ATTAC-II) STUDY, UNITE, IMMUNOMIC THERAPEUTICS, INC.

This is an extension of the Phase 2 ATTAC-II study ( NCT02465268 ) where eligibility is limited to those patients who have had surgery but have not yet received chemoradiation.

Key Points: 
  • This is an extension of the Phase 2 ATTAC-II study ( NCT02465268 ) where eligibility is limited to those patients who have had surgery but have not yet received chemoradiation.
  • ITIs dendritic cell vaccine is designed to target the pp65 viral antigen of Cytomegalovirus (CMV) that is expressed in GBM, but not in normal brain cells.
  • This dendritic cell vaccine is then returned to the patient.
  • The ATTAC-II study ( NCT02465268 ) is a Phase II randomized, placebo-controlled clinical trial enrolling patients with newly diagnosed GBM that will explore whether dendritic cell (DC) vaccines, including ITI-1000, targeting the CMV antigen pp65 improves survival.